Bladder Cancer

The combination induced a response in nearly two-thirds of patients with unresectable locally advanced or metastatic urothelial cancer when used in the frontline setting.

“Histologic variants do express Nectin-4 and Trop-2, the targets of antibody-drug conjugates that are FDA-approved in bladder cancer,” says Fed Ghali, MD.

Fed Ghali, MD, discusses the outlook for patients with variant histology bladder cancer and how antibody-drug conjugates may provide a new treatment option in this setting.

FDA talks have led to a voluntary pause on the development of Vicineum for bladder cancer in the United States.

"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.

The analysis showed promising signs of clinical activity with cabazitaxel/gemcitabine plus pembrolizumab in patients with docetaxel-unresponsive non-muscle invasive urothelial carcinoma of the upper and lower urinary tracts.

In this interview, Sanjay Patel, MD, discusses blue light cystoscopy for the detection of bladder cancer.

“There are numerous trials that say that if you use blue light cystoscopy, in about 25% of patients, it will help you pick up a tumor you otherwise would have missed with traditional white light cystoscopy,” says Sanjay Patel, MD.

The approval is based on the randomized, double-blind phase 3 CheckMate -274 trial, which previously supported FDA approval of the immunotherapy in this setting.

Belzupacap sarotalocan is a virus-like drug conjugate that consists of a virus-like particle conjugated with an anticancer agent.

“To have at the 2-year mark basically half the patients still without evidence of disease is really a step forward,” says Sam S. Chang, MD, MBA.

“What’s really exciting over the next few years is how are these antibody-drug conjugates that are already FDA-approved going to partner with other current drugs that we can use to treat this disease, such as immunotherapy,” says Garmezy.

"A key overarching question is whether there is just a higher burden/stage of disease “beyond which we don’t think a bladder preservation is likely to provide durable disease control,” says Neil Desai, MD.

“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.

“Your best bladder is the one you were born with,” says Neil Desai, MD.

On this episode of Cleveland Clinic’s Cancer Advances podcast, Byron Lee, MD, PhD, discusses optimizing surgical options for patients with bladder cancer.

In the phase 1b COSMIC-021 trial, the combination of cabozantinib and atezolizumab showed clinical activity with manageable toxicity across several setting in urothelial carcinoma.

Based on previously reported CheckMate-274 data, the FDA approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma.

Randomized controlled trial compares intracorporeal robotic technique with open surgery.

Guru P. Sonpavde, MD, discusses the 2022 ASCO Annual Meeting abstract, “Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.”

Sumanta K. Pal, MD, highlights next steps now that the combination of cabozantinib and atezolizumab showed promising clinical activity in bladder cancer in the phase 1b COSMIC-021 trial.

Guru P. Sonpavde, MD, highlights long-term data from the phase 3 EV-301 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

Pal highlights results from the phase 1b COSMIC-021 trial in which cabozantinib plus atezolizumab showed promising clinical activity in patients with urothelial carcinoma.

In this interview, Eila C. Skinner, MD, discusses neobladder reconstruction in patients undergoing radical cystectomy.

"It's not perfect; you have to sort of retrain it, and there are some downsides to it. But it's the closest that we can get to, essentially, an artificial bladder," says Eila C. Skinner, MD.